Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7440-7450

  Weiss, Geoffrey R ^a   Grosh, William W ^a   Chianese Bullock, Kimberly A ^a   Zhao, Yingdong ^b   Liu, Hui ^c   Slingluff Jr , Craig L ^a   Marincola, Francesco M ^c   Wang, Ena ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; FAMOTIDINE; IBUPROFEN; PARACETAMOL; RECOMBINANT INTERLEUKIN 2;

ADAPTIVE IMMUNITY; ADULT; AGED; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; INNATE IMMUNITY; MALE; MELANOMA; METASTASIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; TUMOR MICROENVIRONMENT;

EID: 82555205468     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1650     Document Type: Article

References (44)

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1998;17:2105-16. (Pubitemid 29318842)
2. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342S-6S. (Pubitemid 39287489)
3. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82. (Pubitemid 32730084)
4. Atkins MB, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome in interleukin-2 therapy of renal cancer. Clin Cancer Res 2005;11:3714-21. (Pubitemid 40685588)
5. Panelli MC, Wang E, Marincola FM. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res 2005;11:3601-3. (Pubitemid 40685573)
6. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y, et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6. (Pubitemid 34728828)
7. Sullivan RJ, Hoshida Y, Brunet J, Tahan S, Aldridge J, Kwab C, et al. A single center experience with high-dose IL-2 treatment of patients with advanced melanoma and pilot investigation of novel gene expression signature as a predictor of response. J Clin Oncol 2009;27:A9003.
8. Gajewski TF, Zha Y, Thurner B, Schuler G. Association of gene expression profile in melanoma and survival to a dentritic cell-based vaccine. J Clin Oncol 2009;27:A9002.
9. Louahed J, Grusell O, Gaulis S, Coche T, Eggermont AM, Kruit W, et al. Expression of defined genes indentifed by pre-treatment tumor profiling: association with clinical response to GSK MAGE A-3 immunetherapeutic in metastatic melanoma patients. J Clin Oncol 2008;26:A9045.
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4. (Pubitemid 44498003)
11. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors, a prognostic factor that should not be ignored. Oncogene 2009;29:1093-102.
12. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Murtas D, Chouchane L, et al. An immunologic portrait of cancer. J Transl Med 2011;9:146.
13. Ascierto ML, Kmieciak M, Idowo MO, Manjili R, Zhao Y, Grimes M', et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2011 Apr 11. [Epub ahead of print].
14. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008;29:256-62.
15. Wang E, Marincola FM, editors. Immunologic signatures of rejection. 1st ed. New York: Springer; 2010.
16. Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today 2000;21:619-23. (Pubitemid 32044018)
17. Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM. High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nature Biotech 2000;17:457-9. (Pubitemid 30217539)
18. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002;3:R35.
19. Panelli MC, Stashower M, Slade HB, Smith K, Norwood C, Abati A, et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2006;8:R8.
20. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, et al. Gene expression profiling of cutaneous wound healing. J Transl Med 2007;5:11.
21. Simon R, Lam A, LI MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-Array tools. Cancer Inform 2007;3:11-7. (Pubitemid 47075796)
22. Jin P, Wang E, Provenzano M, Deola S, Selleri S, Jiaqiang R, et al. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med 2006;4:26.
23. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66. (Pubitemid 41817714)
24. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38. (Pubitemid 36818782)
25. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. a IFN-g and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. (Pubitemid 32391043)
26. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
27. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. (Pubitemid 36077915)
28. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996;174:116-28. (Pubitemid 26426204)
29. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011;23:286-92.
30. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007;25 Suppl 2:B61-71. (Pubitemid 47488551)
31. Hamid O, Chasalow SD, Tsuchihashi Z, Alaparthy S, Galbraith S, Berman D. Association of baseline and on-study tumor biopsy markers with clinical activity in patients with advanced melanoma treated with ipilimumab. J Clin Oncol 2009;27:A9008.
32. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24:3164-71. (Pubitemid 46638955)
33. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facets of oncolytic therapy. BMC Genomics 2009;10:301.
34. Wang E, Marincola FM. cDNA microarrays and the enigma of melanoma immune responsiveness. Cancer J Sci Am 2001;7:16-23. (Pubitemid 32199099)
35. Panelli MC, White RL Jr, Foster M, Martin B, Wang E, Smith K, et al. Forecasting the cytokine storm following systemic interleukin-2 administration. J Transl Med 2004;2:17.
36. Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro' V, et al. A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 2003;177:124-31. (Pubitemid 39279468)
37. Rossi L, Martin B, Hortin G, White RL Jr, Foster M, Stroncek D, et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006;6:709-20. (Pubitemid 43208049)
38. Gajewski TF. Transcriptional profiling of melanoma as a potential predictive biomarker for response to immunotherapy. In: Wang E, Marincola FM, editors. Signatures of rejection. New York: Springer; 2010. p. 229-38.
39. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009;69:3077-85.
40. Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother 2010;33:965-74.
41. Salk J. Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 1969;164:365-80.
42. Wang E, Marincola FM. From the "delayed allergy reaction" to the "immunologic constant of rejection". In: Wang E, Marincola FM, editors. Immunologic signatures of rejection. New York: Springer; 2010. p. 3-8.
43. Carretero R, Wang E, Rodriguez A, Reinboth J, Ascierto ML, Engle AM, et al. Regression of melanoma metastases is associated with activation of antigen presentation and immune-mediated rejection genes. Int J Cancer 2001 Sep 30 [Epub ahead of print].
44. Marincola FM. The trouble with translational medicine. J Intern Med 2011;270:123-7.